Eli Lilly

USA · Pharma & Healthcare

LeaveRussia detail: Withdrawal

Exited Russia

Eli Lilly and Company is an American pharmaceutical company.

Status last verified 03/08/2026Source checked 24/09/2025Company website ↗LeaveRussia profile ↗

Decision trail

Decision date 11/04/2023 · Reference ↗

Suspend new investments and clinical trials. The American pharmaceutical company Eli Lilly has decided to leave Russia and transfer its business to its partner in Central and Eastern Europe — the Swiss-registered distributor Swixx Biopharma. The company will hand over business in the country to Swixx BioPharma. Through it, Eli Lilly will continue to supply drugs to Russia. The American Eli Lilly has banned the supply of Humalog insulin to Russia. Revenue significantly (by -99%) decreased in 2024 vs 2023.

Local stats (LeaveRussia)

Assets(RF), mln.USD

Capital(RF), mln.USD

Glob.Revenue, mln.USD

34124

Revenue(RF), mln.USD

Staff(RF), 2021

147

Taxes(RF), mln.USD

Status history since 2022

03/08/2026 — exited · Imported from KSE LeaveRussia

Exposure profile

Full exposure profile is a Professional feature

Energy, transport and commodity exposure, supplier/customer links in the region and sanctioned-party proximity.

Upgrade to Professional